United States : Today, Lupin Limited (Lupin), a leading global pharmaceutical company, revealed the rollout of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, subsequent to obtaining approval from the United States Food and Drug Administration (U.S. FDA).
- The Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe serves as a generic counterpart to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL, produced by Organon USA LLC. It is prescribed for preventing premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
- The Ganirelix Acetate Injection recorded approximate annual sales of USD 87 million in the U.S. market, according to IQVIA MAT data from December 2023.